Search
Invitrogen
Docetaxel Recombinant Mouse Monoclonal Antibody (4B10)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
图: 1 / 1
Docetaxel Antibody (MA566533) in SDS-PAGE
SDS-PAGE characterization of Docetaxel under reducing conditions. Lane M: Protein marker (kDa); Lane DOC: Purified Docetaxel Recombinant Monoclonal (Product # MA566533). Docetaxel showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-334.
产品信息
MA566533
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
4B10
抗原
Conjugate of DOC hapten and KLH.
偶联物
形式
Liquid
浓度
7.5 mg/mL
规格
200 µg
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
RRID
靶标信息
Docetaxel, marketed commonly under the brand name Taxotere, is a chemotherapeutic agent classified as a taxane, actively utilized in the treatment of various cancers including breast, ovarian, prostate, and non-small cell lung cancer. Structurally, docetaxel is a semisynthetic analogue of paclitaxel, featuring a taxane ring with functional groups that enhance its solubility and therapeutic efficacy. Its mechanism of action involves the stabilization of microtubules, preventing their disassembly during cell division, thereby inhibiting mitosis and inducing apoptosis in cancer cells. Administered through intravenous infusion, docetaxel's pharmacokinetic profile includes extensive tissue distribution and metabolism primarily by the liver enzyme CYP3A4. While effective in managing cancer, docetaxel's use is associated with potential side effects, such as neutropenia, fluid retention, and hypersensitivity reactions, necessitating careful monitoring during treatment. Ongoing research aims to optimize dosing regimens and explore combination therapies that enhance its anticancer activity while minimizing toxicities.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
